-
New confocal fluorescence imaging minimizes photobleaching and phototoxicity effects, capturing clear images of live 3D culture
-
Industry-leading throughput enables real-time analysis of up to six microplates in parallel, maximizing data generation
-
Comprehensive, intuitive workflows with integrated data analysis empower every scientist to generate high-quality data from complex assays with greater speed and confidence
Future Medical Products LLC Announces the Launch of PBME Topical™ (Pure Bone Marrow Exosomes)
July 24, 2025, St. Louis, Missouri — Future Medical Products LLC is pleased to announce the launch of PBME Topical (“Pure Bone Marrow Exosomes”). PBME Topical is a cosmetic product in compliance with the Modernization of Cosmetics Regulation Act of 2022 (MoCRA).
PBME Topical consists of isolated exosomes from mesenchymal stem cells, the most studied cell in science. These exosomes are composed of phospholipid bilayers with transmembrane proteins and receptors, integrated growth factors, in addition to micro-RNA and messenger-RNA. Exosomes are naturally found in every part of the body, but the source of the exosomes intended for aesthetics, as well as regenerative medicine, is critical. Bone marrow exosomes are considered by some to be the purest form of stem cell therapy without the cell. [Read more…]
Vita Therapeutics and I Peace announced a development program to generate iPS- derived differentiated cells for transplant therapy with an initial focus on FSHD (Facioscapulohumeral Muscular Dystrophy) using universal iPS cells
Palo Alto, CA, July 10, 2025 – Leading GMP cell CDMO I Peace, Inc., specializing in induced pluripotent stem cells (iPSCs) and iPSC-derived cell therapies, announced that the company has agreed with Vita Therapeutics (Vita) to jointly develop universal iPS cells that will be used for cell transplantation therapy.
GMP-grade iPS cells will be modified with proprietary, licensed gene editing technology to make a base platform hypoimmune line where Class I and II HLA genes that determine rejection have been depleted. These hypoimmune lines can be further customized in I Peace cGMP facilities. [Read more…]
Ciloa secures €6.5 million government funding from France 2030 ‘Innovation in biotherapies and biomanufacturing’ to develop drug candidate for treatment of obesity and type 2 diabetes
-
‘DIADEME’ project awarded €6.5 million in government funding via France 2030, enabling Ciloa to advance the development of its bio-drug APN-sEV (Adiponectin associated with exosomes), the world’s only recombinant, stable and functional form of Adiponectin
-
First preclinical results confirm remarkable therapeutic potential in treatment of several metabolic diseases, in particular type 2 diabetes and obesity, affecting around two billion patients worldwide
-
Ciloa plans to use funding to implement biomanufacturing of candidate APN-sEV and demonstrate that innovative biotherapy meets all safety criteria to enter clinical phases I and IIa in treatment of obesity and type 2 diabetes
Applied StemCell Launches hiEX™ Research iPSC Exosomes to Power Next-Generation Regenerative Medicine Research
MILPITAS, Calif., June 24, 2025 — Applied StemCell, a leading provider of advanced stem cell and gene editing technologies since 2008, today announced the release of hiEX™ Research iPSC Exosomes, a new research-use-only product designed to enable scientists to explore the therapeutic potential of iPSC-derived exosomes in areas such as wound healing, aging, and nerve regeneration. [Read more…]
- « Previous Page
- 1
- …
- 12
- 13
- 14
- 15
- 16
- …
- 20
- Next Page »